HOTH - Spark Newswire

1 minute read

FDA
News

Hoth Therapeutics Announces It Has Successfully Completed Manufacturing Feasibility Of The HT-KIT Drug Substance

Today, 5:03 PM

Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced development updates for its cancer therapeutic, HT-KIT after receiving Orphan Drug Designation from

HOTH

6 minute read

94 Biggest Movers From Friday

By Lisa Levin

Today, 5:03 PM

Gainers Marygold Companies (NYSE: MGLD) shares surged 89.4% to close at $4.11 on Friday after dropping 21% on Thursday. TeraWulf Inc. (NASDAQ: WULF) gained 49.3% to close at $9.51.

ACRX

3 minute read

50 Stocks Moving In Friday’s Mid-Day Session

By Lisa Levin

Today, 5:03 PM

Gainers Marygold Companies (NYSE: MGLD) jumped 189.4% to $6.28 after dropping 21% on Thursday.

AEI

1 minute read

Hoth Therapeutics PR Announces Orphan Drug Designation Granted To Cancer Therapeutic HT-KIT To Treat Mastocytosis

By Bill Haddad

Today, 5:03 PM

NEW YORK, March 11, 2022 /PR Newswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA)

HOTH

3 minute read

30 Stocks Moving in Friday’s Pre-Market Session

By Lisa Levin

Today, 5:03 PM

AAU

5 minute read

78 Biggest Movers From Yesterday

By Lisa Levin

Today, 5:03 PM

Gainers Hycroft Mining Holding Corporation (NASDAQ: HYMC) shares jumped 138.1% to close at $1.50 on Thursday after dropping 37% on Wednesday.

AAU

1 minute read

Hoth Therapeutics Shares Spike Higher On Volume Following Circulation Of FDA AccessData.gov Listing For Orphan Drug Designation Of Co.’s C-KIT-Targeting Candidate

By Benzinga Newsdesk

Today, 5:03 PM

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=866521

HOTH

2 minute read

24 Stocks Moving in Friday’s Pre-Market Session

By Lisa Levin

Today, 5:03 PM

Gainers Statera Biopharma, Inc. (NASDAQ: STAB) rose 30.4% to $0.9520 in pre-market trading. Statera Biopharma recently submitted Phase 1 clinical trial protocol to the FDA for investigational treatment of long-haul COVID-19.

CEMI